About this Journal Submit a Manuscript Table of Contents
Arthritis
Volume 2010 (2010), Article ID 106202, 10 pages
http://dx.doi.org/10.1155/2010/106202
Review Article

Macrophage Migration Inhibitory Factor: A Multifunctional Cytokine in Rheumatic Diseases

1Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo 142-8666, Japan
2Department of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan

Received 18 July 2010; Revised 4 December 2010; Accepted 21 December 2010

Academic Editor: Marco Matucci-Cerinic

Copyright © 2010 Tsuyoshi Kasama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Lee and M. E. Weinblatt, “Rheumatoid arthritis,” Lancet, vol. 358, no. 9285, pp. 903–911, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. E. Koch, S. L. Kunkel, and R. M. Strieter, “Cytokines in rheumatoid arthritis,” Journal of Investigative Medicine, vol. 43, no. 1, pp. 28–38, 1995. View at Scopus
  4. S. L. Kunkel, N. Lukacs, T. Kasama, and R. M. Strieter, “The role of chemokines in inflammatory joint disease,” Journal of Leukocyte Biology, vol. 59, no. 1, pp. 6–12, 1996. View at Scopus
  5. Z. Szekanecz, G. Szücs, S. Szántó, and A. E. Koch, “Chemokines in rheumatic diseases,” Current Drug Targets, vol. 7, no. 1, pp. 91–102, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Brennan and J. Beech, “Update on cytokines in rheumatoid arthritis,” Current Opinion in Rheumatology, vol. 19, no. 3, pp. 296–301, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. B. R. Bloom and E. Shevach, “Requirement for T cells in the production of migration inhibitory factor,” Journal of Experimental Medicine, vol. 142, no. 5, pp. 1306–1311, 1975. View at Scopus
  8. T. Calandra and T. Roger, “Macrophage migration inhibitory factor: a regulator of innate immunity,” Nature Reviews Immunology, vol. 3, no. 10, pp. 791–800, 2003. View at Scopus
  9. M. Bacher, C. N. Metz, and C. N. Metz, “An essential regulatory role for macrophage migration inhibitory factor in T-cell activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 15, pp. 7849–7854, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Calandra, J. Bernhagen, R. A. Mitchell, and R. Bucala, “The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor,” Journal of Experimental Medicine, vol. 179, no. 6, pp. 1895–1902, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Nishihira, Y. Koyama, and Y. Mizue, “Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide,” Cytokine, vol. 10, no. 3, pp. 199–205, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. A. G. Rossi, C. Haslett, and C. Haslett, “Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF): potential role in asthma,” Journal of Clinical Investigation, vol. 101, no. 12, pp. 2869–2874, 1998. View at Scopus
  13. A. Daryadel, R. F. Grifone, H. U. Simon, and S. Yousefi, “Apoptotic neutrophils release macrophage migration inhibitory factor upon stimulation with tumor necrosis factor-α,” Journal of Biological Chemistry, vol. 281, no. 37, pp. 27653–27661, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. K. Imamura, J. Nishihira, and J. Nishihira, “Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney,” Biochemistry and Molecular Biology International, vol. 40, no. 6, pp. 1233–1242, 1996. View at Scopus
  15. Z. Chen, M. Sakuma, and M. Sakuma, “Evidence for a Role of Macrophage Migration Inhibitory Factor in Vascular Disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 4, pp. 709–714, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. Leech, C. Metz, and C. Metz, “Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1601–1608, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Bernhagen, T. Calandra, and T. Calandra, “MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia,” Nature, vol. 365, no. 6448, pp. 756–759, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. R. A. Mitchell, C. N. Metz, T. Peng, and R. Bucala, “Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF): regulatory role in cell proliferation and glucocorticoid action,” Journal of Biological Chemistry, vol. 274, no. 25, pp. 18100–18106, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Calandra, J. Bernhagen, and J. Bernhagen, “MIF as a glucocorticoid-induced modulator of cytokine production,” Nature, vol. 377, no. 6544, pp. 68–71, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. Martin, J.-C. Weber, and J.-C. Weber, “Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis,” Arthritis and Rheumatism, vol. 43, no. 4, pp. 827–833, 2000. View at Publisher · View at Google Scholar
  21. R. A. Mitchell, H. Liao, J. Chesney, G. Fingerle-Rowsor, J. Baugh, J. David, and R. Bucala, “Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 345–350, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. G. H. Tesch, D. J. Nikolic-Paterson, and D. J. Nikolic-Paterson, “Rat mesangial cells express macrophage migration inhibitory factor in vitro and in vivo,” Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 417–424, 1998. View at Scopus
  23. D. F. Larson and K. Horak, “Macrophage migration inhibitory factor: controller of systemic inflammation,” Critical Care, vol. 10, no. 2, article 138, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. E. F. Morand, M. Leech, and J. Bernhagen, “MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis,” Nature Reviews Drug Discovery, vol. 5, no. 5, pp. 399–411, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. N. C. Riedemann, R. F. Guo, and R. F. Guo, “Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils,” Journal of Immunology, vol. 173, no. 2, pp. 1355–1359, 2004. View at Scopus
  26. M. F. Roelofs, L. A. B. Joosten, and L. A. B. Joosten, “The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells,” Arthritis and Rheumatism, vol. 52, no. 8, pp. 2313–2322, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. C. Popa, A. W. T. van Lieshout, and A. W. T. van Lieshout, “MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis,” Cytokine, vol. 36, no. 1-2, pp. 51–56, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. C. N. Paiva, R. H. Arras, and R. H. Arras, “Migration inhibitory factor (MIF) released by macrophages upon recognition of immune complexes is critical to inflammation in Arthus reaction,” Journal of Leukocyte Biology, vol. 85, no. 5, pp. 855–861, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. L. Leng, C. N. Metz, and C. N. Metz, “MIF signal transduction initiated by binding to CD74,” Journal of Experimental Medicine, vol. 197, no. 11, pp. 1467–1476, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. X. Shi, L. Leng, and L. Leng, “CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex,” Immunity, vol. 25, no. 4, pp. 595–606, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. K. L. Meyer-Siegler, K. A. Iczkowski, L. Leng, R. Bucala, and P. L. Vera, “Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells,” Journal of Immunology, vol. 177, no. 12, pp. 8730–8739, 2006. View at Scopus
  32. J. Bernhagen, R. Krohn, and R. Krohn, “MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment,” Nature Medicine, vol. 13, no. 5, pp. 587–596, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. J. B. Lubetsky, A. Dios, and A. Dios, “The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents,” Journal of Biological Chemistry, vol. 277, no. 28, pp. 24976–24982, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. L. Leng, L. Chen, J. Fan, et al., “A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice,” Journal of Immunology, vol. 186, no. 1, pp. 527–538, 2011.
  35. J. Bernhagen, T. Calandra, and R. Bucala, “Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features,” Journal of Molecular Medicine, vol. 76, no. 3-4, pp. 151–161, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Petrovsky, L. Socha, D. Silva, A. B. Grossman, C. Metz, and R. Bucala, “Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator,” Immunology and Cell Biology, vol. 81, no. 2, pp. 137–143, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. G. Fingerle-Rowson, P. Koch, and P. Koch, “Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo,” American Journal of Pathology, vol. 162, no. 1, pp. 47–56, 2003. View at Scopus
  38. L. Santos, P. Hall, C. Metz, R. Bucala, and E. F. Morand, “Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids,” Clinical and Experimental Immunology, vol. 123, no. 2, pp. 309–314, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Calandra and R. Bucala, “Macrophage migration inhibitory factor (MIF): a glucocorticoid counter- regulator within the immune system,” Critical Reviews in Immunology, vol. 17, no. 1, pp. 77–88, 1997. View at Scopus
  40. J. L. Gregory, M. T. Leech, J. R. David, Y. H. Yang, A. Dacumos, and M. J. Hickey, “Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice,” Arthritis and Rheumatism, vol. 50, no. 9, pp. 3023–3034, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. M. Leech, C. Metz, L. Santos, T. Peng, S. R. Holdsworth, R. Bucala, and E. F. Morand, “Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis,” Arthritis and Rheumatism, vol. 41, no. 5, pp. 910–917, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Makita, M. Nishimura, and M. Nishimura, “Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 2, pp. 573–579, 1998. View at Scopus
  43. A. Schober, J. Bernhagen, and J. Bernhagen, “Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice,” Circulation, vol. 109, no. 3, pp. 380–385, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. J. L. Gregory, E. F. Morand, and E. F. Morand, “Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2,” Journal of Immunology, vol. 177, no. 11, pp. 8072–8079, 2006. View at Scopus
  45. T. Okamoto, T. Atsumi, C. Shimizu, N. Yoshioka, and T. Koike, “The potential role of macrophage migration inhibitory factor on the migration of vascular smooth muscle cells,” Journal of Atherosclerosis and Thrombosis, vol. 15, no. 1, pp. 13–19, 2008. View at Scopus
  46. M. Dewor, G. Steffens, R. Krohn, C. Weber, J. Baron, and J. Bernhagen, “Macrophage migration inhibitory factor (MIF) promotes fibroblast migration in scratch-wounded monolayers in vitro,” FEBS Letters, vol. 581, no. 24, pp. 4734–4742, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. Y. Yang, P. Degranpré, A. Kharfi, and A. Akoum, “Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 12, pp. 4721–4727, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Matsui, H. Okamoto, N. Jia, M. Akino, T. Uede, A. Kitabatake, and J. Nishihira, “Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis,” Journal of Molecular and Cellular Cardiology, vol. 37, no. 2, pp. 557–566, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. J. L. Gregory, P. Hall, M. Leech, E. F. Morand, and M. J. Hickey, “Independent roles of macrophage migration inhibitory factor and endogenous, but not exogenous glucocorticoids in regulating leukocyte trafficking,” Microcirculation, vol. 16, no. 8, pp. 735–748, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. Q. Cheng, S. J. McKeown, L. Santos, F. S. Santiago, L. M. Khachigian, E. F. Morand, and M. J. Hickey, “Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules,” Journal of Immunology, vol. 185, no. 2, pp. 1238–1247, 2010. View at Publisher · View at Google Scholar · View at PubMed
  51. R. W. McMurray, “Adhesion molecules in autoimmune disease,” Seminars in Arthritis and Rheumatism, vol. 25, no. 4, pp. 215–233, 1996. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Onodera, K. Kaneda, Y. Mizue, Y. Koyama, M. Fujinaga, and J. Nishihira, “Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis,” Journal of Biological Chemistry, vol. 275, no. 1, pp. 444–450, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. J. C. M. Morel, C. C. Park, J. M. Woods, and A. E. Koch, “A novel role for interleukin-18 in adhesion molecule induction through NFκB and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways,” Journal of Biological Chemistry, vol. 276, no. 40, pp. 37069–37075, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. Y. P. De Jong, A. C. Abadia-Molina, and A. C. Abadia-Molina, “Development of chronic colitis is dependent on the cytokine MIF,” Nature Immunology, vol. 2, no. 11, pp. 1061–1066, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. J. C. M. Morel, C. C. Park, K. Zhu, P. Kumar, J. H. Ruth, and A. E. Koch, “Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression,” Journal of Biological Chemistry, vol. 277, no. 38, pp. 34679–34691, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. M. Tuyet Nguyen, H. Lue, and H. Lue, “The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis,” Journal of Immunology, vol. 170, no. 6, pp. 3337–3347, 2003. View at Scopus
  57. S. Onodera, J. Nishihira, and J. Nishihira, “Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1β,” Arthritis and Rheumatism, vol. 50, no. 5, pp. 1437–1447, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. S. G. Lin, X. I. Y. Yu, and X. I. Y. Yu, “De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits,” Circulation Research, vol. 87, no. 12, pp. 1202–1208, 2000. View at Scopus
  59. M. A. Amin, C. S. Haas, K. Zhu, P. J. Mansfield, M. J. Kim, N. P. Lackowski, and A. E. Koch, “Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFκB,” Blood, vol. 107, no. 6, pp. 2252–2261, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. T. Calandra, L. A. Spiegel, C. N. Metz, and R. Bucala, “Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 19, pp. 11383–11388, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Y. Lan, M. Bacher, and M. Bacher, “The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat,” Journal of Experimental Medicine, vol. 185, no. 8, pp. 1455–1465, 1997. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Bozza, A. R. Satoskar, G. Lin, B. Lu, A. A. Humbles, C. Gerard, and J. R. David, “Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis,” Journal of Experimental Medicine, vol. 189, no. 2, pp. 341–346, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Roger, J. David, M. P. Glauser, and T. Calandra, “MIF regulates innate immune responses through modulation of Toll-like receptor 4,” Nature, vol. 414, no. 6866, pp. 920–924, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. D. Lacey, A. Sampey, R. Mitchell, R. Bucala, L. Santos, M. Leech, and E. Morand, “Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor,” Arthritis and Rheumatism, vol. 48, no. 1, pp. 103–109, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. S. Stosic-Grujicic, I. Stojanovic, and I. Stojanovic, “Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus,” Journal of Cellular Physiology, vol. 215, no. 3, pp. 665–675, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. D. J. Cua, J. Sherlock, and J. Sherlock, “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain,” Nature, vol. 421, no. 6924, pp. 744–748, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. M. A. Hoeve, N. D. L. Savage, T. de Boer, D. M. L. Langenberg, R. de Waal Malefyt, T. H. M. Ottenhoff, and F. A. W. Verreck, “Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells,” European Journal of Immunology, vol. 36, no. 3, pp. 661–670, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. F. Q. Cunha, W. Y. Weiser, J. R. David, D. W. Moss, S. Moncada, and F. Y. Liew, “Recombinant migration inhibitory factor induces nitric oxide synthase in murine macrophages,” Journal of Immunology, vol. 150, no. 5, pp. 1908–1912, 1993. View at Scopus
  69. F. Y. Liew, “Regulation of nitric oxide synthesis in infectious and autoimmune diseases,” Immunology Letters, vol. 43, no. 1-2, pp. 95–98, 1994. View at Publisher · View at Google Scholar · View at Scopus
  70. C. F. Nathan, T. J. Prendergast, and M. E. Wiebe, “Activation of human macrophages. Comparison of other cytokines with interferon-γ,” Journal of Experimental Medicine, vol. 160, no. 2, pp. 600–605, 1984.
  71. C. M. Denkinger, M. Denkinger, J. J. Kort, C. Metz, and T. G. Forsthuber, “In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system,” Journal of Immunology, vol. 170, no. 3, pp. 1274–1282, 2003. View at Scopus
  72. H. R. Kim, MI. K. Park, and MI. K. Park, “Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 5, pp. 927–936, 2007. View at Scopus
  73. P. K. Bondza, C. N. Metz, and A. Akoum, “Macrophage migration inhibitory factor up-regulates alpha(v)beta(3) integrin and vascular endothelial growth factor expression in endometrial adenocarcinoma cell line Ishikawa,” Journal of Reproductive Immunology, vol. 77, no. 2, pp. 142–151, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. E. F. Morand, M. Leech, H. Weedon, C. Metz, R. Bucala, and M. D. Smith, “Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations,” Rheumatology, vol. 41, no. 5, pp. 558–562, 2002. View at Scopus
  75. F. De Benedetti, C. Meazza, and C. Meazza, “Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis,” Arthritis and Rheumatism, vol. 48, no. 5, pp. 1398–1407, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. R. Donn, Z. Alourfi, and Z. Alourfi, “A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis,” Arthritis and Rheumatism, vol. 50, no. 5, pp. 1604–1610, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. A. Mikulowska, C. N. Metz, R. Bucala, and R. Holmdahl, “Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-lnduced arthritis in mice,” Journal of Immunology, vol. 158, no. 11, pp. 5514–5517, 1997. View at Scopus
  78. M. Leech, D. Lacey, and D. Lacey, “Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis,” Arthritis and Rheumatism, vol. 48, no. 7, pp. 1881–1889, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. C. A. Wijbrandts, S. I. Van Leuven, H. D. Boom, D. M. Gerlag, E. G. S. Stroes, J. J. P. Kastelein, and P. P. Tak, “Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 8, pp. 1316–1321, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. M. Budarf, T. McDonald, B. Sellinger, C. Kozak, C. Graham, and G. Wistow, “Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q11.2,” Genomics, vol. 39, no. 2, pp. 235–236, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. J. A. Baugh, S. Chitnis, and S. Chitnis, “A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis,” Genes and Immunity, vol. 3, no. 3, pp. 170–176, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. A. Barton, R. Lamb, D. Symmons, A. Silman, W. Thomson, J. Worthington, and R. Donn, “Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis,” Genes and Immunity, vol. 4, no. 7, pp. 487–491, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. A. Martínez, G. Orozco, and G. Orozco, “Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility,” Human Immunology, vol. 68, no. 9, pp. 744–747, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. T. R. D. J. Radstake, F. C. G. J. Sweep, and F. C. G. J. Sweep, “Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor,” Arthritis and Rheumatism, vol. 52, no. 10, pp. 3020–3029, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. A. Foote, E. M. Briganti, Y. Kipen, L. Santos, M. Leech, and E. F. Morand, “Macrophage migration inhibitory factor in systemic lupus erythematosus,” Journal of Rheumatology, vol. 31, no. 2, pp. 268–273, 2004. View at Scopus
  86. H. Y. Lan, N. Yang, and N. Yang, “Expression of macrophage migration inhibitory factor in human glomerulonephritis,” Kidney International, vol. 57, no. 2, pp. 499–509, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. E. Sánchez, L. M. Gómez, and L. M. Gómez, “Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus,” Genes and Immunity, vol. 7, no. 5, pp. 433–436, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. A. Y. Hoi, M. J. Hickey, and M. J. Hickey, “Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice,” Journal of Immunology, vol. 177, no. 8, pp. 5687–5696, 2006. View at Scopus
  89. K. Matsumoto, N. Maruyama, and N. Maruyama, “Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis,” Clinical and Experimental Immunology, vol. 139, no. 2, pp. 338–347, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. H. Y. Lan, W. Mu, and W. Mu, “De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis,” American Journal of Pathology, vol. 149, no. 4, pp. 1119–1127, 1996. View at Scopus
  91. F. G. Brown, D. J. Nikolic-Paterson, P. A. Hill, N. M. Isbel, J. Dowling, C. M. Metz, and R. C. Atkins, “Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis,” Journal of the American Society of Nephrology, vol. 13, supplement 1, pp. S7–S13, 2001.
  92. D. H. Lovett, J. L. Ryan, and R. B. Sterzel, “A thymocyte-activating factor derived from glomerular mesangial cells,” Journal of Immunology, vol. 130, no. 4, pp. 1796–1801, 1983. View at Scopus
  93. T. Ohkawara, J. Nishihira, and J. Nishihira, “Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice,” Gastroenterology, vol. 123, no. 1, pp. 256–270, 2002. View at Publisher · View at Google Scholar
  94. H. Kanemitsu, M. Matsunawa, and M. Matsunawa, “Increased serum levels of macrophage migration inhibitory factor (MIF) in patients with microscopic polyangiitis,” Open Access Rheumatology: Research and Reviews, vol. 1, no. 1, pp. 1–8, 2009.
  95. H. Becker, C. Maaser, E. Mickholz, A. Dyong, W. Domschke, and M. Gaubitz, “Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides,” Clinical Rheumatology, vol. 25, no. 3, pp. 368–372, 2006. View at Publisher · View at Google Scholar · View at PubMed
  96. T. J. Lee, J. K. Chun, S. I. Yeon, J. S. Shin, and D. S. Kim, “Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease,” Scandinavian Journal of Rheumatology, vol. 36, no. 3, pp. 222–225, 2007. View at Publisher · View at Google Scholar · View at PubMed
  97. E. Selvi, S. A. Tripodi, and S. A. Tripodi, “Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 62, no. 5, pp. 460–464, 2003. View at Publisher · View at Google Scholar
  98. P. Willeke, M. Gaubitz, H. Schotte, C. Maaser, W. Domschke, B. Schlüter, and H. Becker, “Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome,” Arthritis Research and Therapy, vol. 9, article R43, 2007. View at Publisher · View at Google Scholar · View at PubMed
  99. L. D. Kozaci, I. Sari, A. Alacacioglu, S. Akar, and N. Akkoc, “Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor,” Modern Rheumatology, vol. 20, no. 1, pp. 34–39, 2010. View at Publisher · View at Google Scholar · View at PubMed
  100. YU. Q. Zou, L. J. Lu, and L. J. Lu, “The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease,” Clinical Biochemistry, vol. 41, no. 7-8, pp. 519–524, 2008. View at Publisher · View at Google Scholar · View at PubMed
  101. R. Ohwatari, Y. Inuyama, S. Fukuda, K. Onoé, K. Iwabuchi, and J. Nishihira, “Serum level of macrophage migration inhibitory factor as a useful parameter of clinical course in patients with Wegener's granulomatosis and relapsing polychondritis,” Annals of Otology, Rhinology and Laryngology, vol. 110, no. 11, pp. 1035–1040, 2001.
  102. P. A. Johnson, H. D. Alexander, S. A. McMillan, and A. P. Maxwell, “Up-regulation of the endothelial cell adhesion molecule intercellular adhesion molecule-1 (ICAM-1) by autoantibodies in autoimmune vasculitis,” Clinical and Experimental Immunology, vol. 108, no. 2, pp. 234–242, 1997.
  103. J. S. Sundy and B. F. Haynes, “Cytokines and adhesion molecules in the pathogenesis of vasculitis,” Current rheumatology reports, vol. 2, no. 5, pp. 402–410, 2000.
  104. A. D. Filer, J. M. Gardner-Medwin, and J. M. Gardner-Medwin, “Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa,” Annals of the Rheumatic Diseases, vol. 62, no. 2, pp. 162–167, 2003. View at Publisher · View at Google Scholar
  105. R. A. Sinico, A. Radice, C. Corace, L. Di Toma, and E. Sabadini, “Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis,” Annals of the New York Academy of Sciences, vol. 1050, pp. 185–192, 2005. View at Publisher · View at Google Scholar · View at PubMed
  106. J. Chesney, C. Metz, M. Bacher, T. Peng, A. Meinhardt, and R. Bucala, “An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma,” Molecular Medicine, vol. 5, no. 3, pp. 181–191, 1999.
  107. S. Kotake, N. Kitaichi, and S. Ohno, “Macrophage migration inhibitory factor in uveitis,” International Ophthalmology Clinics, vol. 42, no. 1, pp. 99–103, 2002.